TIER IV, the pioneering force behind the world's first open-source software for autonomous driving, and Nihon Kotsu, Tokyo's largest taxi company, launched a pioneering project in Februaryto collect driving data using taxis equipped with a data recording system (DRS) developed by TIER IV. The aim of the project is to develop generative AI that will […]
Report on how AI is driving market transformation – The globalcorporate training marketsize is estimated to grow by USD 43.86 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 7.8% during the forecast period. Emergence of cost-effective e-learning training modulesis driving market growth,with a trend towardsemergence of iot
(NYSE:MG), PRINCETON JUNCTION, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) — The Board of Directors of MISTRAS Group, Inc. (NYSE: MG) is deeply saddened to announce the passing of Dr. Sotirios J. Vahaviolos, the company's Founder, Chairman Emeritus, and Board Director, on Thursday, February 6, 2025. A visionary leader and pioneer in the field of non-destructive
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Universal Display Corporation ("Universal Display Corporation") (NASDAQ:OLED) concerning possible violations of federal securities laws. On August 1, 2024, Universal reported solid 2Q 2024 results and raised the bottom-end of its full year
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=127724&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
(NasdaqGM:SION), BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) — Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the pricing of its upsized initial
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=127730&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your FTAI Aviation Ltd. (NASDAQ:FTAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ftai-aviation-ltd-lawsuit-submission-form?prid=127729&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=127728&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Nextracker Inc. (NASDAQ:NXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/nextracker-inc-lawsuit-submission-form?prid=127726&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call